Patents by Inventor Helge Roider
Helge Roider has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240400700Abstract: The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.Type: ApplicationFiled: May 16, 2024Publication date: December 5, 2024Applicant: Bayer AktiengesellschaftInventors: Sandra Berndt, Christian Bertling, Pascale Buchmann, Philipp Ellinger, Katharina Filarsky, Matyas Gorjanacz, Sabine Maria Hoff, Nikolaus Pawlowski, Helge Roider, Beatrix Stelte-Ludwig, Mark Trautwein, Ernst Weber, Uwe Gritzan, Oliver von Ahsen, Christian Votsmeier, Wiebke Maria Nadler, Patrick Jones, Pedro Paz, Su-Yi Tseng, Phaik Lyn Oh
-
Publication number: 20240376218Abstract: The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.Type: ApplicationFiled: May 16, 2024Publication date: November 14, 2024Applicant: Bayer AktiengesellschaftInventors: Sandra Berndt, Christian Bertling, Pascale Buchmann, Philipp Ellinger, Katharina Filarsky, Matyas Gorjanacz, Sabine Maria Hoff, Nikolaus Pawlowski, Helge Roider, Beatrix Stelte-Ludwig, Mark Trautwein, Ernst Weber, Uwe Gritzan, Oliver von Ahsen, Christian Votsmeier, Wiebke Maria Nadler, Patrick Jones, Pedro Paz, Su-Yi Tseng, Phaik Lyn Oh
-
Patent number: 12065497Abstract: The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.Type: GrantFiled: April 22, 2022Date of Patent: August 20, 2024Assignee: Bayer AktiengesellschaftInventors: Sandra Berndt, Christian Bertling, Pascale Buchmann, Philipp Ellinger, Katharina Filarsky, Matyas Gorjanacz, Sabine Hoff, Nikolaus Pawlowski, Helge Roider, Beatrix Stelte-Ludwig, Mark Trautwein, Ernst Weber, Uwe Gritzan, Oliver von Ahsen, Christian Votsmeier, Wiebke Maria Nadler, Patrick Jones, Pedro Paz, Su-Yi Tseng, Phaik Lyn Oh
-
Publication number: 20240108766Abstract: The present invention relates to conjugates comprising a chelator arranged for complexation of a radionuclide and a targeting moiety binding to LRRC15. For example, the conjugates according to the current invention can be targeted alpha therapeutics such as targeted thorium conjugates (TTCs), i.e. radioconjugates comprising an alpha emitter, such as 227Th. The present invention further relates to sequence-defined antibodies binding LRRC15 and antigen-binding fragments thereof. Also provided are conjugates comprising these antibodies or functional fragments thereof. The antibodies, functional fragments and conjugates according to the current invention can be used to treat cancer and other disorders and conditions associated with the expression of LRRC15.Type: ApplicationFiled: January 17, 2022Publication date: April 4, 2024Inventors: Mark TRAUTWEIN, Urs Beat HAGEMANN, Phillipp ELLINGER, Stephan MAERSCH, Joachim SCHUHMACHER, Antje WENGNER, Roger Malerbakken BJERKE, Helge ROIDER
-
Publication number: 20230250178Abstract: The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.Type: ApplicationFiled: June 25, 2021Publication date: August 10, 2023Inventors: Sandra BERNDT, Katharina FILARSKY, Philipp ELLINGER, Beatrix STELTE-LUDWIG, Sabine HOFF, Helge ROIDER, Ernst WEBER, Mark TRAUTWEIN, Christian VOTSMEIER, Nikolaus PAWLOWSKI, Uwe GRITZAN, Pascale BUCHMANN, Christian BERTLING, Oliver VON AHSEN, Wiebke Maria NADLER, Su-Yi TSENG, Pedro PAZ, Phaik Lyn OH, Patrick JONES, Matyas GORJANACZ
-
Publication number: 20220363768Abstract: The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.Type: ApplicationFiled: April 22, 2022Publication date: November 17, 2022Inventors: Sandra Berndt, Katharina Filarsky, Sabine Hoff, Helge Roider, Uwe Gritzan, Christian Votsmeier, Wiebke Maria Nadler, Su-Yi Tseng
-
Patent number: 11427640Abstract: The present invention relates to tools and methods for the generation of antibodies which specifically bind chemokine receptors, such as CC or CXC chemokine receptors. Provided are isolated sulfated polypeptides and conjugates thereof, which can be used for example as antigens or for off target panning to facilitate the generation of anti-human, anti-cynomolgus, and/or anti-mouse chemokine receptor antibodies, e.g. for the generation of antibodies with fully human CDRs and/or other favorable properties for therapeutic use. The present invention furthermore relates to antibodies and conjugates thereof which can be obtained by applying the aforementioned tools and methods. Provided are antibodies specifically binding to human, cynomolgus and/or murine CCR8 with favorable properties for therapeutic use, such as cross-reactive antibodies, fully human antibodies, low internalizing (including non-internalizing) antibodies, and antibodies efficiently inducing ADCC and/or ADCP in Treg cells.Type: GrantFiled: June 25, 2021Date of Patent: August 30, 2022Assignee: BAYER AKTIENGESELLSCHAFTInventors: Sandra Berndt, Katharina Filarsky, Sabine Hoff, Helge Roider, Uwe Gritzan, Christian Votsmeier, Wiebke Maria Nadler, Su-Yi Tseng